^
Association details:
Biomarker:BRAF V600
Cancer:Melanoma
Drug:Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Excerpt:
...Written documentation of BRAF V600E mutation, or any other BRAF V600 mutation....
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Title:

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells

Published date:
11/28/2020
Excerpt:
...concurrent use of encorafenib and selective MCL-1 inhibitor can potentiate apoptosis in BRAFV600 melanoma and reduce the likelihood of developing drug resistance…
Secondary therapy:
S63845
DOI:
doi.org/10.1016/j.canlet.2020.11.036